An internal standard for the quantification of trelagliptin
Related Products
Unlabeled Version(s)
18504Trelagliptin
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Trelagliptin-13C-d3

Item No. 28203

Technical Information
Formal Name
(R)-2-((6-(3-aminopiperidin-1-yl)-3-(methyl-13C-d3)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzonitrile
CAS Number
2707203-34-5
Molecular Formula
C17[13C]H17D3FN5O2
Formula Weight
Purity
≥99% deuterated forms (d1-d3)
Formulation
A solid
SMILES
O=C(N([13C]([2H])([2H])[2H])C(N1CC2=CC(F)=CC=C2C#N)=O)C=C1N3CCC[C@@H](N)C3
InChi Code
InChI=1S/C18H20FN5O2/c1-22-17(25)8-16(23-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14(19)5-4-12(13)9-20/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3/t15-/m1/s1/i1+1D3
InChi Key
IWYJYHUNXVAVAA-GKOPAMJVSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Trelagliptin-13C-d3 is intended for use as an internal standard for the quantification of trelagliptin (Item No. 18504) by GC- or LC-MS. Trelagliptin is an inhibitor of dipeptidyl peptidase 4 (DPP-4; IC50 = 4 nM).1 It is greater than 10,000-fold selective for DPP-4 over isopeptidases. Trelagliptin (7 mg/kg) inhibits plasma DPP-4 activity and reduces postprandial plasma insulin levels in Zucker fa/fa rats. Formulations containing trelagliptin have been used in the treatment of type 2 diabetes mellitus.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kushwaha, R.N., Haq, W., and Katti, S.B. Discovery of 17 gliptins in 17-years of research for the treatment of type 2 diabetes: A synthetic overview. Chem. Biol. Interface 4(3), 137-162 (2014).